Organic synthesis and enzymatic assays Core 1 - Ali, UMASS Medical School Drug resistance is a major limitation in the treatment of many pathogenic infections and cancers. Understanding the mechanisms of drug resistance and developing strategies to avoid resistance could lead to more effective treatments. Due to the plethora of available data, HIV-1 protease is a unique model system to study the mechanisms of drug resistance. In this highly interdisciplinary Program Project, we aim to elucidate the molecular mechanisms of drug resistance in HIV-1 protease and develop drug design strategies to avoid resistance. The Core 1 will provide medicinal chemistry support to the members of the Program Project. We will synthesize protease inhibitors and analogues required for co-crystallization, ITC, NMR, and resistance selection studies. We will work closely with the computational and structural biology groups to design new inhibitors using multiple core scaffolds that fully leverage the interdependence of different sub-sites in HIV-1 protease recognition. We will carry out the chemical synthesis of designed inhibitors and evaluate their activities in enzymatic assays against wild-type protease and drug-resistant variants. This highly collaborative and integrated approach will help elucidate the mechanisms of drug resistance and provide strategies to design more robust inhibitors less susceptible to drug resistance.

Public Health Relevance

Organic synthesis and enzymatic assays Core 1 - Ali, UMASS Medical School HIV-1 protease inhibitors are the most potent antiretroviral drugs for the treatment of HIV infection, but their efficacy is limited due to the rapid acquisition of drug resistance. HIV-1 protease provides a unique opportunity to understand the molecular mechanisms of drug resistance and develop strategies for avoiding drug resistance. The Core 1 will provide medicinal chemistry support to the members of the Program Project, work closely with Project 3 and synthesize protease inhibitors and analogues required for the experimental studies in Projects 1 and 2.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Program Projects (P01)
Project #
1P01GM109767-01A1
Application #
8789528
Study Section
Special Emphasis Panel (ZRG1)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-07-31
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
City
Worcester
State
MA
Country
United States
Zip Code
01655
Kurt Yilmaz, Nese; Swanstrom, Ronald; Schiffer, Celia A (2016) Improving Viral Protease Inhibitors to Counter Drug Resistance. Trends Microbiol 24:547-57
Özer, Nevra; Özen, Ayşegül; Schiffer, Celia A et al. (2015) Drug-resistant HIV-1 protease regains functional dynamics through cleavage site coevolution. Evol Appl 8:185-98
Potempa, Marc; Nalivaika, Ellen; Ragland, Debra et al. (2015) A Direct Interaction with RNA Dramatically Enhances the Catalytic Activity of the HIV-1 Protease In Vitro. J Mol Biol 427:2360-78
Zhou, Hao; Li, Shangyang; Badger, John et al. (2015) Modulation of HIV protease flexibility by the T80N mutation. Proteins 83:1929-39
Ishima, Rieko (2015) Effects of radiation damping for biomolecular NMR experiments in solution: a hemisphere concept for water suppression. Concepts Magn Reson Part A Bridg Educ Res 44A:252-262
Cai, Yufeng; Myint, Wazo; Paulsen, Janet L et al. (2014) Drug Resistance Mutations Alter Dynamics of Inhibitor-Bound HIV-1 Protease. J Chem Theory Comput 10:3438-3448
Ragland, Debra A; Nalivaika, Ellen A; Nalam, Madhavi N L et al. (2014) Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease. J Am Chem Soc 136:11956-63
Kolli, Madhavi; Ozen, Ayşegül; Kurt-Yilmaz, Nese et al. (2014) HIV-1 protease-substrate coevolution in nelfinavir resistance. J Virol 88:7145-54
Özen, Ayşegül; Lin, Kuan-Hung; Kurt Yilmaz, Nese et al. (2014) Structural basis and distal effects of Gag substrate coevolution in drug resistance to HIV-1 protease. Proc Natl Acad Sci U S A 111:15993-8